Head to head comparison of two PET/CT imaging agents, [18F]D3FSP ([18F]P16-129) and [18F]AV45, in patients with alzheimer’s disease
Abstract Background A new β-amyloid (Aβ) targeting radiotracer, [18F]D3FSP ([18F]P16-129), for diagnosis of Alzheimer’s disease (AD) is reported. This radiotracer is a deuterated N-methyl derivative of Amyvid (AV-45, florbetapir f18) which was FDA-approved in 2013. Deuteration may alter a tracer’s P...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-06-01
|
| Series: | EJNMMI Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13550-025-01276-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Background A new β-amyloid (Aβ) targeting radiotracer, [18F]D3FSP ([18F]P16-129), for diagnosis of Alzheimer’s disease (AD) is reported. This radiotracer is a deuterated N-methyl derivative of Amyvid (AV-45, florbetapir f18) which was FDA-approved in 2013. Deuteration may alter a tracer’s PK such that imaging performance is improved. A head-to-head comparison between these two imaging agents was conducted in AD patients. A separate biodistribution study was conducted on six healthy subjects, and radiation dosimetry estimation was obtained. Results Eight patients, clinically diagnosed with Alzheimer’s disease, had an average age of 61.1 ± 10.0 years, and an average MMSE score of 21 ± 4. Each patient underwent paired 90-minute dynamic PET/CT scans separately within a few weeks (323 ± 31 MBq of [18F]D3FSP or [18F]AV45; florbetapir f18). SUVR (50–70 min) and Distribution Volume Ratio (DVR) of 43 brain regions were evaluated. The average SUVR across cortical gray matter was 1.65 ± 0.21 for [18F]AV45 and 1.65 ± 0.23 for [18F]D3FSP, while global DVRs were 1.36 ± 0.14 and 1.37 ± 0.13 for [18F]AV45 and [18F]D3FSP respectively. Strong correlations (R2 = 0.8–0.9) were observed between tracers for both SUVR and DVR, with slopes of ~ 0.9 (SUVR) and ~ 1 (DVR). No image artifacts or confounds influenced the visual interpretation of [18F]D3FSP compared to [18F]AV45. Conclusions Results showed no difference between [18F]D3FSP and [18F]AV45 and no benefit of deuteration at the N-methyl site. Even so, [18F]D3FSP may be a useful alternative for PET/CT imaging of Aβ deposits in the brain as its binding characteristics were very similar to its non-deuterated analog, the FDA-approved drug [18F]AV45. Trial registration Clinicaltrials.org, NCT03902548. Registered 01/07/2018. |
|---|---|
| ISSN: | 2191-219X |